New antibody drug ‘reduces hospital admission or death from Covid-19 by 85%’

Pharmaceutical giant GlaxoSmithKline has said a monoclonal antibody drug reduces hospital admission or death from Covid-19 by 85% (Andy Buchanan/PA)

A monoclonal antibody drug reduces hospital admission or death from Covid-19 by 85%, the pharmaceutical giant GlaxoSmithKline (GSK) has announced.

The drug, called VIR-7831, is a new treatment for people with mild to moderate illness, and the study has been so successful that it has been stopped early.